Intact Investment Management’s Moderna MRNA Stock Holding History

Intact Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,100	Closed	-$420K	–	350
2024 Q4	$420K	Buy	+10,100	New	+$483K	0.01%	246

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Intact Investment Management's MRNA Position: Q1 2025 in Review

Intact Investment Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 10,100 shares — an estimated $420K sold.

Intact Investment Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $420K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

Intact Investment Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
Intact Investment Management sold 10,100 Moderna shares in Q1 2025, an estimated $420K.
Intact Investment Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
Intact Investment Management's Moderna position peaked at $420K in Q4 2024.
693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Intact Investment Management's 13F filing for Q1 2025, filed 22 Apr 2025.